Has Rebecca Eng received payments from drug or device companies?

Yes. Drug and device makers reported $7,009 in general payments to Rebecca Eng across 375 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rebecca Eng did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rebecca Eng come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rebecca Eng

Family · Kennewick, WANPI 1265661342

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.2% of the total across 375 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 26 manufacturers reported payments, led by AbbVie at 24.3% of the total. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,009in general payments, 2019–2025

Across 375 payments — averaging $18.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$2K
Johnson & Johnson$1K
Lilly USA, LLC$879
Regeneron Healthcare Solutions, Inc.$561
Amgen$543
UCB, Inc.$411
plus $2K from 20 others

What the payments were for

Food & beverage$6,53393%
Education$4767%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	110	$1,700
Johnson & Johnson	66	$1,038
Lilly USA, LLC	48	$879
Regeneron Healthcare Solutions, Inc.	18	$561
Amgen	18	$543
UCB, Inc.	27	$411
Novartis	13	$266
E.r. Squibb & Sons, L.L.C.	15	$253
Sanofi-aventis U.S. LLC	2	$160
Boehringer Ingelheim	5	$150
Sun Pharmaceutical Industries Inc.	4	$141
Galderma Laboratories, L.p.	8	$132
Arcutis Biotherapeutics, Inc.	7	$124
Sanofi	4	$112
LEO Pharma Inc.	5	$105
Incyte Corporation	5	$79
Pfizer	4	$66
Almirall LLC	3	$53
Organon	2	$46
VYNE Pharmaceuticals Inc.	2	$43
Biofrontera Inc.	2	$33
Helsinn Therapeutics (U.S.), Inc.	2	$31
Genentech USA, Inc.	2	$28
Fresenius Kabi USA, LLC	1	$20
Kyowa Kirin, Inc.	1	$18
Dermavant Sciences, Inc.	1	$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Otezla$125
Skyrizi$125
DUPIXENT$120
LIBTAYO$118
Rinvoq$117

How this compares

$7,009 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.

See all family providers in Washington →

Medicare billing

Part B allowed, 2024

$388,778

Medicare patients

1,189

Services billed

9,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Clobetasol Propionate	54	$2,900
Triamcinolone Acetonide	202	$2,542
Fluorouracil	20	$1,920
Metronidazole	42	$1,732
Ketoconazole	103	$1,628
Betamethasone Dipropionate	21	$1,346
Imiquimod	22	$472
Doxycycline Hyclate	43	$444
Nystatin	17	$272
Finasteride	44	$247
Minoxidil	31	$240
Hydroxychloroquine Sulfate	21	$221
ValacyclovirValacyclovir Hcl	23	$209
Fluconazole	23	$153
Gabapentin	12	$108

Paid to pharmacies, not to this prescriber.

Other family in Kennewick

Sharla PetersonKenmore$192K
Zelda SwainSpokane$83K
Savannah MorganRenton$76K
Kevan PettersonSeattle$56K
Kelly McFeeSunnyside$42K
Cheryl SomersSpokane$31K
Hye-Jin GehringBellevue$30K
Kaitlin BrasierSeattle$29K
Karen JohnsonSeattle$16K
Brittanee WorthySpokane Valley$15K

See the full list for Washington →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →